Genetic testing covered by companies that make treatments for primary hyperoxaluria can help identify cases of this rare condition, which often leads to kidney failure at an early age.

Alnylam Pharmaceuticals, Inc., maker of the lumasiran (Oxlumo) , partnered with Prevention Genetics, a unit of Exact Sciences Corporation, to run a testing program free of charge for individuals in the US and Canada. Novo Nordisk, maker of nedosiran (Rivfloza) , works with Blueprint Genetics on a similar program.

These programs make it easier for physicians treating patients whose medical histories raise concerns about possible primary hyperoxaluria, said Matthew Breeggemann, MD, a nephrologist and co-medical director of the UCSF’s Kidney Stone Prevention Clinic.

The test kits are mailed to patie

See Full Page